CoChat
Sign Up
Cited by 107Metabolism, Diabetes, and CancerCancer Risks and FactorsDiabetes Treatment and Management

Cancer risks in thiazolidinedione users compared to other anti-diabetic agents

Koro, Carol, Barrett, Steven, Qizilbash, Nawab·2007·Pharmacoepidemiology and Drug Safety
DOI 10.1002/pds.1352
Open this paper in CoChat — free account

Abstract

PURPOSE: We conducted three nested case-control studies to evaluate the risk of breast, colon, and prostate cancers developing in patients exposed to thiazolidinediones (TZDs) compared with other anti-diabetic agents. METHODS: Cancer cases were matched to five controls by age, gender, calendar year, and time in the database from a cohort of 1 26 971 diabetic patients taking anti-diabetic medication in the US Integrated Healthcare Information Services database. Five hundred thirteen breast cancer cases were matched with 2557 controls, 408 cases of colon cancer were matched with 2027 controls and 643 cases of prostate cancer were matched with 3176 controls. Exposure to an anti-diabetic agent within 90 days preceding the index date was defined as recent exposure and at any time during the follow-up was defined as ever exposed. RESULTS: The adjusted odds ratios and 95%CI of cancer from ever exposure to TZDs compared to oral monotherapy, oral dual therapy, oral triple therapy, insulin monotherapy, insulin and oral therapy and all non-TZD anti-diabetic agents were, respectively for breast cancer: 0.91 (0.69-1.20), 0.80 (0.56-1.14), 0.87 (0.32-2.35), 1.27 (0.61-2.67), 0.71 (0.36-1.37), 0.89 (0.68-1.15); for colon cancer: 1.06 (0.80-1.40), 1.12 (0.77-1.63), 1.73 (0.39-7.78), 4.46 (1.05-19.00), 1.06 (0.50-2.26) 1.03 (0.80-1.32) and for prostate cancer: 1.08 (0.85-1.37), 0.89 (0.66-1.21); 0.82 (0.33-2.06); 1.80 (0.79-4.07), 1.10 (0.55-2.18), 1.04 (0.83-1.31). Results for exposure within 90 days of the date of the cancer were similar. CONCLUSIONS: Our findings suggest that the effect of TZDs on the likelihood of development of the cancers studied (colon, prostate and breast) appears to be neutral and do not support a beneficial or deleterious effect of TZD on the cancers studied.

Integrity signals

Registry

Crossref · 10.1002/pds.1352

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Three epidemiologic studies among patients with diabetes focused on all cancers combined or only on a limited number of cancer sites, and results were inconsistent.

    “Three epidemiologic studies conducted among patients with diabetes focused on all cancers combined or only on a limited number of cancer sites, and results were inconsistent (104–106).”

    From Diabetes and Cancer (2010) · cites this paper as [104]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Koro, C., Barrett, S., & Qizilbash, N.
Affiliations
  • GlaxoSmithKline (United States) (US)
  • University of London (GB)
Corresponding author
Qizilbash, Nawab
ORCID
Qizilbash, Nawab
Venue
Pharmacoepidemiology and Drug Safety
Publisher
Wiley
Published
2006-12-27
Volume
16
Issue
5
Pages
485-492
ISSN
  • 1053-8569 (ISSN-L)
  • 1099-1557
DOI
10.1002/pds.1352
OpenAlex
W1971343583
Cited by
107
References
28
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 6 · 2017: 2 · 2015: 8 · 2014: 12 · 2013: 11 · 2012: 14
FWCI
2.45
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Pharmacoepidemiology and Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
Funders
GlaxoSmithKline
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Oncology › Cancer Risks and Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
thiazolidinediones, cancer risk, breast cancer, colon cancer, prostate cancer, antidiabetic drugs, diabetes mellitus, insulin therapy, oral antidiabetic drugs, drug safety
MeSH terms
Administration, Oral, Adolescent, Adult, Aged, Breast Neoplasms, Colonic Neoplasms, Delivery of Health Care, Diabetes Mellitus, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Neoplasms, Prostatic Neoplasms, United States, Odds Ratio, Case-Control Studies, Databases, Factual, Risk Assessment, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review